论文部分内容阅读
近20年高血压的药物治疗已取得很大的进展,治疗高血压的各类药物不断地被研究开发出来。其中较新型的药物是:血管紧张素转换酶抑制剂(ACEI)和AT拮抗剂。它们的作用机制均为抑制肾素—血管紧张素系统。这两类制剂在临床上的应用,无疑为治疗高血压及心衰提供了新的手段。随着临床研究的不断深入,它们的应用范围仍在不断拓宽。现将它们在临床上的应用状况简介如下: 1 ACEI 自从1997年卡托普利(captopril 开搏通)上市之后正式作为第一代口服的ACEI治疗高血压获得了良效以后。目前已陆续开发出一系列这类药物,除第一代卡托普利外,均是长效型,但各种制剂间有一定差异,除卡
Nearly 20 years of hypertension drug treatment has made great progress, the treatment of various types of drugs continue to be developed hypertension. Among the newer drugs are: angiotensin-converting enzyme inhibitors (ACEIs) and AT antagonists. Their mechanism of action is to inhibit the renin-angiotensin system. The clinical application of these two types of preparations, no doubt for the treatment of hypertension and heart failure provides a new means. With the deepening of clinical research, their applications are still expanding. Their clinical application is now briefly described as follows: 1 ACEI since 1997 when captopril (Captopril) was officially listed as the first generation of oral ACEI treatment of hypertension obtained good effect later. Has been gradually developed a series of these drugs, in addition to the first generation of captopril, are long-acting, but there are some differences between the various preparations, in addition to the card